- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03047980
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients ages 3 to 31 years of age, inclusive.
Cognitive impairment as defined by the following:
SWS cognitive neuroscore of ≥ 1
- Ability to participate in direct neuropsychological and developmental testing.
- English as primary language.
- Stable anti-epileptic drugs (no changes in medications except dose for >3 months).
- Adequate renal function. GFR must be greater than 50 ml/min/m2 as determined by the Schwartz Formula for children and MDRD for adults: http://www.nkdep.nih.gov/professionals/gfr_calculators/index.htm
- If female and of child bearing potential, documentation of a negative pregnancy test prior to enrollment determined by a urine test is required. Sexually active pre-menopausal female patients (and female partners of male patients) must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on the study drug. Abstinence will be considered an adequate contraceptive measure.
- INR ≤1.5 (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks.)
Adequate liver function as shown by:
- Serum bilirubin ≤ 1.5x ULN
- ALT and AST ≤ 2.5x ULN
- Written informed consent according to local guidelines. Local guidelines for subject assent will also be followed.
- Stable dose of medications affecting the cytochrome P 450 3A4 (CYP3A4) and p glycoprotein (P gp) systems for at least 3 months prior to consent.
Exclusion Criteria:
- Allergy to sirolimus or other rapamycin analogues.
- Patients with seizures secondary to metabolic, toxic, infectious or psychogenic disorder, drug abuse or current seizures related to an acute medical illness.
- Inability to keep follow-up appointments, maintain close contact with Principal Investigators, and/or complete all necessary studies to maintain safety.
- Patients in need of immediate major surgical intervention.
- Concurrent severe and/or uncontrolled medical disease, which could compromise participation in the pilot study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration, impaired or restrictive pulmonary function, pneumonitis or pulmonary infiltrates).
- Chronic treatment with systemic steroids or another immunosuppressive agent. Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Inhaled steroids are allowed.
- Known history of HIV seropositivity or known immunodeficiency. Testing is not required unless a condition is suspected.
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sirolimus (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A gastric tube or nasogastric tube is allowed.
- Patients with an active, bleeding diathesis.
- Patients with uncontrolled hyperlipidemia: fasting serum cholesterol > 300 mg/dL AND fasting triglycerides > 2.5 x ULN.
- Patients who have had a major surgery or significant traumatic injury within four weeks of study entry. Patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the pilot study.
- Patients with a prior history of organ transplant.
- Patients who have received live attenuated vaccines within one week of start of sirolimus and during the pilot study.
- Patients who have a history of malignancy.
- Patients who are currently part of or have participated in any clinical investigation with an investigational drug within one month prior to enrollment.
- Patients being treated with felbamate, unless treatment has been continuous for ≥ one year.
- Patients currently receiving anticancer therapies or who have received anticancer therapies within four weeks of study entry (including chemotherapy, radiation therapy, antibody based therapy, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus
All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis.
The drug will be taken for six months.
|
Low dose oral sirolimus
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cognitive Function as Assessed by the National Institute of Health (NIH) Toolbox Cognitive Battery
Time Frame: Baseline and at 6 months on the study drug
|
Change over six months in cognitive functioning in Sturge-Weber syndrome is the primary outcome measure. This outcome will be assessed using the NIH Toolbox Cognitive Battery, a panel of testing which includes the following measures:
These scores are rescaled to T scores (mean = 50, standard deviation (SD) = 10), referenced against the US population. Higher scores indicate better outcome. T scores only were analyzed. |
Baseline and at 6 months on the study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in Mean Power Asymmetry of the Occipital Alpha Frequency Band
Time Frame: Baseline and at 6months on the study drug
|
Change in mean laterality score (by qEEG power analysis) was done comparing hemispheres and occipital lobes in the following frequency bands; delta, theta, alpha, beta, as previously described.
As post-hoc analysis, baseline and follow-up qEEG of patients with and without stroke-like episodes were compared.
Greater asymmetry with decreased power on the affected side is worse.
We calculated a mean Laterality Score (LSb) for each band, averaged over 30 epochs and included channel pairs.
Laterality Scores less than zero indicate lower power on the side ipsilateral to the port wine birthmark.
In subjects who had a bilateral port wine birthmark, the side of maximal involvement was used (or the side of known involvement by MRI findings, where present).
|
Baseline and at 6months on the study drug
|
Change in Sturge-Weber Syndrome Clinical Neuroscore
Time Frame: Baseline and at 6 months on the study drug
|
Change in clinical neuroscore over the course of the study were measured.
The neuroscore is comprised of frequency of seizures (0-4) , extent of hemiparesis (0-4), assessment of visual field cut (0-2) , and degree of cognitive functioning (0-5) with a minimum total score of 0 and a maximum total score of 15.
Higher scores mean worsening of symptoms.
|
Baseline and at 6 months on the study drug
|
Number of Participants With a Change in Sturge-Weber Syndrome Birthmark Score
Time Frame: Visits at 2 weeks (baseline) and 28 weeks (study end)
|
Frontal and profile photograph will be taken under standardized conditions with scoring of the port-wine birthmark for percent of face covered, thickness of birthmark, and darkness of birthmark color.
|
Visits at 2 weeks (baseline) and 28 weeks (study end)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne M Comi, M.D., Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neurocognitive Disorders
- Disease
- Brain Ischemia
- Cognition Disorders
- Infarction
- Stroke
- Brain Infarction
- Hemangioma
- Neoplasms, Vascular Tissue
- Neurocutaneous Syndromes
- Angiomatosis
- Syndrome
- Cognitive Dysfunction
- Klippel-Trenaunay-Weber Syndrome
- Sturge-Weber Syndrome
- Brain Stem Infarctions
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- IRB00079722
- 2U54NS065705 (U.S. NIH Grant/Contract)
- BVMC6209 (Other Grant/Funding Number: Rare Diseases Clinical Research Network)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sturge-Weber Syndrome
-
Johns Hopkins UniversityVascular Birthmarks FoundationCompletedEpilepsy | Sturge Weber SyndromeUnited States
-
University of California, IrvineMainz UniversityCompletedSturge - Weber Syndrome (SWS)United States
-
Wills EyeUniversity of Medicine and Dentistry of New JerseyTerminatedSturge Weber Syndrome | Port-wine MarkUnited States
-
Baylor College of MedicineNovartis PharmaceuticalsWithdrawnSturge Weber SyndromeUnited States
-
Clinica Universidad de Navarra, Universidad de...Completed
-
Qlaris Bio, Inc.CompletedOcular Hypertension | Glaucoma | Glaucoma Congenital | Sturge-Weber Syndrome (SWS)United States
-
University of Illinois at ChicagoWayne State University; Boston Children's Hospital; Duke University; University... and other collaboratorsRecruitingSturge-Weber SyndromeUnited States
-
Anne Comi, MDJazz Pharmaceuticals; Faneca 66 FoundationCompletedSturge-Weber SyndromeUnited States
-
University Hospital, ToursCompletedPort Wine Stain | Parkes Weber Syndrome | Klippel Trenaunay SyndromeFrance
-
Wayne State UniversityNational Institutes of Health (NIH)Recruiting
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States